Literature DB >> 32458096

Early changes in bone turnover predict longer-term changes in bone mineral density but not trabecular bone score in frail older women.

Mary P Kotlarczyk1, Subashan Perera2, Neil M Resnick2, David A Nace2, Susan L Greenspan2.   

Abstract

Clinicians and patients want to know if therapy is working early in their course of treatment. We found that early changes in bone turnover markers at 6 months were associated with long-term changes in bone mineral density but not trabecular bone score at 12 and 24 months.
PURPOSE: We sought to examine the association between shorter-term changes in markers of bone turnover and longer-term changes in bone mineral density (BMD) and microstructure in a cohort of frail elderly women with multiple comorbid conditions including osteoporosis.
METHODS: We performed a secondary analysis of a 2-year zoledronic acid trial for osteoporosis in 155 women residents of long-term care communities (mean age 86.9 years). We examined the association of the 6-month change in serum C-terminal crosslinking telopeptide of type I collagen (CTX) and serum intact procollagen type I N propeptide (PINP) with the 12- and 24-month changes in BMD at the spine and hip and the trabecular bone score (TBS), an indirect measure of bone microstructure.
RESULTS: For every 0.2-ng/ml 6-month CTX decrease, the corresponding increase in spine BMD at 12 and 24 months was 0.2% (p = 0.7210) and 1.1% (p = 0.0396), respectively; total hip BMD 1.1% (p = 0.0279) and 0.9% (p = 0.0716); and femoral neck BMD 1.7% (p = 0.0079) and 0.9% (p = 0.1698). Similarly, for every 20-ng/ml 6-month PINP decrease, the corresponding increase in spine BMD at 12 and 24 months was 0.9% (p = 0.0286) and 1.4% (p = 0.0012), respectively; total hip BMD 1.4% (p = 0.0005) and 1.4% (p = 0.0006); and femoral neck BMD 2.3% (p < 0.0001) and 2.0% (p < 0.0001). Bone marker changes were not consistently associated with TBS changes.
CONCLUSION: Shorter-term 6-month changes in bone turnover markers are associated with the long-term changes in BMD over 1-2 years in the spine and hip but not with TBS.

Entities:  

Keywords:  Bone mineral density; Bone turnover markers; Elderly; Osteoporosis; Trabecular bone score

Mesh:

Substances:

Year:  2020        PMID: 32458096      PMCID: PMC8006805          DOI: 10.1007/s11657-020-00749-w

Source DB:  PubMed          Journal:  Arch Osteoporos            Impact factor:   2.617


  37 in total

1.  Co-morbidity adjustment for functional outcomes in community-dwelling older adults.

Authors:  Sally K Rigler; Stephanie Studenski; Dennis Wallace; Dean M Reker; Pamela W Duncan
Journal:  Clin Rehabil       Date:  2002-06       Impact factor: 3.477

2.  Clinical Use of Bone Turnover Markers.

Authors:  Douglas C Bauer
Journal:  JAMA       Date:  2019-08-13       Impact factor: 56.272

3.  Frailty in older adults: evidence for a phenotype.

Authors:  L P Fried; C M Tangen; J Walston; A B Newman; C Hirsch; J Gottdiener; T Seeman; R Tracy; W J Kop; G Burke; M A McBurnie
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2001-03       Impact factor: 6.053

4.  Efficacy and safety of single-dose zoledronic acid for osteoporosis in frail elderly women: a randomized clinical trial.

Authors:  Susan L Greenspan; Subashan Perera; Mary Anne Ferchak; David A Nace; Neil M Resnick
Journal:  JAMA Intern Med       Date:  2015-06       Impact factor: 21.873

5.  Prediction of changes in bone mineral density in postmenopausal women treated with once-weekly bisphosphonates.

Authors:  Sherri-Ann M Burnett-Bowie; Kenneth Saag; Anthony Sebba; Anne E de Papp; Erluo Chen; Elizabeth Rosenberg; Susan L Greenspan
Journal:  J Clin Endocrinol Metab       Date:  2009-01-13       Impact factor: 5.958

6.  The effect of bisphosphosphonates on bone turnover and bone balance in postmenopausal women with osteoporosis: The T-score bone marker approach in the TRIO study.

Authors:  F Gossiel; M A Paggiosi; K E Naylor; E V McCloskey; J Walsh; N Peel; R Eastell
Journal:  Bone       Date:  2019-11-15       Impact factor: 4.398

7.  Effect of feeding on bone turnover markers and its impact on biological variability of measurements.

Authors:  J A Clowes; R A Hannon; T S Yap; N R Hoyle; A Blumsohn; R Eastell
Journal:  Bone       Date:  2002-06       Impact factor: 4.398

Review 8.  Diagnosis of osteoporosis and assessment of fracture risk.

Authors:  John A Kanis
Journal:  Lancet       Date:  2002-06-01       Impact factor: 79.321

9.  Potential Usefulness of BMD and Bone Turnover Monitoring of Zoledronic Acid Therapy Among Women With Osteoporosis: Secondary Analysis of Randomized Controlled Trial Data.

Authors:  Katy Jl Bell; Andrew Hayen; Paul Glasziou; Les Irwig; Richard Eastell; Stephanie L Harrison; Dennis M Black; Douglas C Bauer
Journal:  J Bone Miner Res       Date:  2016-04-25       Impact factor: 6.741

10.  Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate.

Authors:  R Eastell; I Barton; R A Hannon; A Chines; P Garnero; P D Delmas
Journal:  J Bone Miner Res       Date:  2003-06       Impact factor: 6.741

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.